Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 6Phase 1/2 6Phase 1 3Phase NA 1

Status

Recruiting 6Completed 3Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Recurrence 4Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Endometrial Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × selinexor × Clear all
NCT06158841 2026-05-27

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
228 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Shandong New Time Pharmaceutical Co., LTD

Phase 3 Recruiting
261 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT05611931 2026-04-23

XPORT-EC-042

Karyopharm Therapeutics Inc

Phase 3 Recruiting
276 enrolled
Gynecologic

Endometrial Neoplasms

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 3 Recruiting
390 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital

Phase 3 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡